## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Alain MOUSSY et al.

Title:

2-(3-SUBSTITUTED-ARYL) AMINO-4-

ARYL-THIAZOLES AS TYROSINE KINASE

**INHIBITORS** 

Appl. No.:

10/587,436

International

1/28/2005

Filing Date: 371(c) Date:

Examiner:

Unassigned

Art Unit:

Unassigned

Conf. No.:

5301

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. The documents listed were cited in the Information Disclosure Statement filed in the above-identified application on July 26, 2006, and copies of each non-U.S. patent document and each non-patent document are being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date 28-AUG-2007

T D

FOLEY & LARDNER LLP Customer Number: 22428

Telephone:

(202) 295-4059

Facsimile: (202) 672-5399

\_\_\_

Rouget F. Henschel Attorney for Applicant Registration No. 39,221

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

Substitute for form 1449/PTO				Complete if Known			
	INFORMATION DISCLOSURE			Application Number	10/587,436		
STATEMENT BY APPLICANT  Date Submitted:			ICANT	Filing Date	1/28/2005		
				First Named Inventor	Alain Moussy		
				Art Unit	Unassigned		
(use as many sheets as necessary)				Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	065691-0457		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
		Number-Kind Code <sup>2</sup> (if known)			Passages or Relevant Figures Appear	
		·				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number⁴ Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO 03/004467 A2	01/16/2003	Agouron Pharmaceuticals Inc.		
	B2	WO 03/062215 A1	07/31/2003	Kylix Pharmaceuticals B.V.		
	В3	WO 2004/014903 A1	02/19/2004	AB Science		
	B4	WO 2005/000298 A2	01/06/2005	Triad Therapeutics, Inc.		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>		
	B5	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002328977, Database accession no. BRN: 260633 abstract (Yakagaku Zasshi, vol. 75, 1955, p. 1082).			
	В6	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002328978, Database accession no. BRN: 7227176 abstract (J. Indian Chem. Soc., vol. 71, no. 4, 1994, pp. 205-208).			
	В7	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002328979, Database accession no. BRN: 5076163 abstract (Indian J. Chem. Sect. B, vol. 26, no. 1-12, 1987, pp. 856-860).			
·	B8	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002328980, Database accession no. BRN: 3761233 abstract (Yakugaku Zasshi, vol. 75, 1955, p. 1077).			

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.